Gallium-Labeled Gastrin Analogue and Use Thereof in Imaging Methods for CCKB Receptor-Positive Tumors or Cancers

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent concerns a novel radiopharmaceutical: a Gallium-68 (68Ga)-labeled minigastrin analogue that binds specifically to cholecystokinin B (CCKB) receptors, which are overexpressed in certain tumors, such as small-cell lung cancer (SCLC), extrapulmonary small-cell carcinoma (EPSCC), and medullary thyroid cancer (MTC). When administered to a patient, this compound accumulates in CCKB receptor-positive cancer cells, allowing clear and specific imaging of these tumors using PET (Positron Emission Tomography) scans. The patent also covers a preparation kit enabling hospitals and clinics to produce the radiolabeled compound easily.

Use CasesContent extracted from patent full text and abstract with AI.

• Diagnostic imaging of SCLC, EPSCC, and MTC in cancer patients via PET scans to identify tumors expressing CCKB receptors.
• Pre-selection of patients for targeted radionuclide therapy (e.g., Lu-177-labeled treatment) by identifying those with CCKB receptor-positive tumors.
• Differential diagnosis and assessment of tumor type or spread based on CCKB receptor expression.
• Monitoring treatment response and progression of CCKB receptor-positive tumors.
• Research applications to study CCKB receptor prevalence in various cancers or in drug development targeting this receptor.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly specific tumor imaging due to selective binding to CCKB receptor-positive cells, minimizing background noise from healthy tissue.
• Enables personalized medicine by selecting patients likely to benefit from targeted radiotherapy.
• Convenient and high-resolution tumor visualization using PET imaging technology.
• Reduced side effects and unwanted radiation exposure in patients, since only CCKB receptor-positive tumors are targeted.
• Availability of an easy-to-use kit allows on-site production of the radiopharmaceutical, supporting timely clinical workflows.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a 68Ga-labeled gastrin analogue and its use in peptide receptor radionuclide diagnostic applications. In particular, the present invention relates to a 68Ga-labeled minigastrin analogue for use in a method of imaging one or more cholecystokinin B receptor positive diseases selected from small-cell lung cancer, extrapulmonary small-cell carcinoma and medullary thyroid cancer. It also relates to a kit.